Leerink Partnrs Estimates Xeris Biopharma Q2 Earnings

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) – Investment analysts at Leerink Partnrs issued their Q2 2025 earnings per share (EPS) estimates for shares of Xeris Biopharma in a report released on Monday, May 12th. Leerink Partnrs analyst R. Ruiz forecasts that the company will post earnings of ($0.01) per share for the quarter. The consensus estimate for Xeris Biopharma’s current full-year earnings is ($0.41) per share. Leerink Partnrs also issued estimates for Xeris Biopharma’s Q3 2025 earnings at $0.03 EPS, Q4 2025 earnings at $0.04 EPS, FY2025 earnings at $0.00 EPS, FY2026 earnings at $0.20 EPS, FY2027 earnings at $0.40 EPS and FY2028 earnings at $0.65 EPS.

Xeris Biopharma (NASDAQ:XERS) last announced its quarterly earnings results on Thursday, May 8th. The company reported ($0.06) EPS for the quarter, beating the consensus estimate of ($0.07) by $0.01. The firm had revenue of $57.80 million for the quarter, compared to analysts’ expectations of $57.61 million.

Other equities research analysts have also recently issued research reports about the stock. Craig Hallum upped their price target on shares of Xeris Biopharma from $5.00 to $6.50 and gave the stock a “buy” rating in a research report on Friday, March 7th. Oppenheimer upped their target price on Xeris Biopharma from $6.00 to $7.00 and gave the stock an “outperform” rating in a report on Friday, May 9th. Piper Sandler reaffirmed a “neutral” rating and set a $4.00 target price (up previously from $3.00) on shares of Xeris Biopharma in a research report on Friday, March 7th. Jefferies Financial Group reissued a “buy” rating and issued a $6.00 price target (up from $4.00) on shares of Xeris Biopharma in a research report on Wednesday, January 29th. Finally, HC Wainwright restated a “buy” rating and set a $8.00 price objective (up from $6.60) on shares of Xeris Biopharma in a research note on Friday, March 7th. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $6.25.

Xeris Biopharma Price Performance

Shares of Xeris Biopharma stock opened at $4.79 on Thursday. Xeris Biopharma has a 1 year low of $1.86 and a 1 year high of $6.07. The stock has a market cap of $749.08 million, a price-to-earnings ratio of -10.64 and a beta of 1.10. The firm’s 50-day moving average is $4.71 and its two-hundred day moving average is $3.89.

Hedge Funds Weigh In On Xeris Biopharma

Several hedge funds and other institutional investors have recently modified their holdings of the stock. NewEdge Advisors LLC purchased a new position in shares of Xeris Biopharma in the fourth quarter worth $34,000. R Squared Ltd acquired a new position in shares of Xeris Biopharma in the 4th quarter valued at $42,000. Cibc World Markets Corp purchased a new position in Xeris Biopharma in the 4th quarter worth $44,000. Raymond James Financial Inc. purchased a new position in Xeris Biopharma in the 4th quarter worth $45,000. Finally, Two Sigma Advisers LP acquired a new stake in Xeris Biopharma during the 4th quarter worth about $47,000. 42.75% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Xeris Biopharma news, insider Beth Hecht sold 40,000 shares of the firm’s stock in a transaction dated Thursday, March 20th. The stock was sold at an average price of $5.43, for a total value of $217,200.00. Following the completion of the sale, the insider now owns 1,353,510 shares of the company’s stock, valued at approximately $7,349,559.30. This trade represents a 2.87% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 6.47% of the company’s stock.

About Xeris Biopharma

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.